OB/GYN Clinical Alert
RSSArticles
-
How Does the Genitourinary Syndrome of Menopause Affect Patients?
This analysis of baseline questionnaire responses from 302 individuals enrolled in the MsFLASH Vaginal Health Trial demonstrated that the most commonly reported symptoms were vaginal dryness (94%), pain with vaginal penetration (84%), vulvovaginal pain and soreness (76%), and vulvovaginal irritation (73%). The symptom most often rated severe was pain with vaginal penetration (40%).
-
Mifepristone as a Treatment Option for Adenomyosis
This multicenter, placebo-controlled, double-blind randomized clinical trial was conducted in 10 hospitals in China and enrolled 134 patients with diagnosed adenomyosis to evaluate mifepristone as an effective treatment for adenomyosis pain symptoms. Among the intervention group, 98.1% had total remission of adenomyosis pain symptoms as well as improved secondary outcomes with no serious adverse events. Mifepristone is promising for treating pain from adenomyosis.
-
Perioperative Practice Patterns in the Surgical Treatment of Female Stress Urinary Incontinence
Board-certified urogynecologists had higher surgical volumes of stress incontinence surgeries, were more likely to perform perioperative tasks, and had lower readmission rates compared with non-urogynecologists performing anti-incontinence procedures.
-
The Best Treatment for Heavy Menstrual Bleeding
This randomized controlled trial among 62 individuals compared the 52-mg levonorgestrel intrauterine device to combined oral contraceptives for heavy menstrual bleeding and found that, in the intention-to-treat analyses, there was no significant difference in Menstrual Bleeding Questionnaire scores at six months or 12 months (mean difference, 2.5; 95% confidence interval [CI], -10.0, 5.0; and mean difference, -1.1; 95% CI, -8.7, 6.5, respectively).
-
Why It Is Worth Making Sure All Your Pregnant Patients Receive the Influenza Vaccine
Infants younger than 6 months of age are at risk for severe influenza infections. Vaccination during pregnancy reduces infection and hospitalization risk by nearly 70%.
-
Respiratory Syncytial Virus Infection During Pregnancy
Although women who developed respiratory syncytial virus (RSV) infection during pregnancy had a higher risk of preterm birth compared to those without RSV infection, the risk of miscarriage, stillbirth, low birth weight, and small for gestational age fetus were similar between the RSV and placebo groups.
-
Malaria in Pregnancy — Simplified Treatment Decisions
History, data, and international consensus lead to the same conclusion: Artemether-lumefantrine is the first choice for treatment of uncomplicated falciparum malaria in everyone, even pregnant women.
-
Variables Associated with Resolution and Persistence of Ovarian Cysts
This prospective cohort study evaluated 2,683 individuals with incidental cysts discovered during ovarian cancer screenings to determine what factors are associated with cyst resolution over time. Characteristics such as smaller cysts, septated cysts, younger age, premenopausal status, and family history of ovarian cancer were associated with an increased percentage of cyst resolution overall, and factors including older age and lack of hormone therapy were associated with a faster rate of cyst resolution over time. The findings of this study indicate that different surveillance times may be appropriate, depending on cyst morphology and patient characteristics.
-
Metformin for the Management of Early Gestational Diabetes
The administration of metformin in the early stages of gestational diabetes did not demonstrate superiority over placebo in relation to the need to start insulin therapy prior to delivery, or on fasting blood glucose concentrations ≥ 5.1 mmol/L at either the 32nd or 38th weeks of gestation (composite primary outcome).
-
Oral Contraception and Obesity
This study was a re-analysis of drospirenone 4 mg Phase III efficacy trials comparing 590 non-obese and 325 obese patients who showed equivalent pregnancy rates with Pearl Indices of 3.0 (95% confidence interval [CI], 1.3 to 5.8) and 2.9 (95% CI, 0.8 to 7.3), respectively.